Lonsurf and Skin toxicity - a phase IV clinical study of FDA data

Summary:

Skin toxicity is reported as a side effect among people who take Lonsurf (tipiracil hydrochloride; trifluridine), especially for people who are male, 40-49 old, have been taking the drug for 1 - 6 months also take Fluorouracil, and have Colorectal cancer metastatic.

The phase IV clinical study analyzes which people have Skin toxicity when taking Lonsurf. It is created by eHealthMe based on reports of 10,075 people who have side effects when taking Lonsurf from the FDA, and is updated regularly.

What is Lonsurf?

Lonsurf has active ingredients of tipiracil hydrochloride; trifluridine. eHealthMe is studying from 10,077 Lonsurf users. Check the latest studies of Lonsurf.

What is Skin toxicity?

Skin toxicity (skin damage due to toxin/poison) is found to be associated with 269 drugs and 376 conditions by eHealthMe. Check the latest studies of Skin toxicity.

On Jul, 27, 2026

10,075 people reported to have side effects when taking Lonsurf.
Among them, 13 people (0.13%) have Skin toxicity.

Among these 13 people:

How long have people been on Lonsurf when they have Skin toxicity? *

What is the gender of people who have Skin toxicity when taking Lonsurf? *

female: 0.0 %
male: 100 %

What is the age of people who have Skin toxicity when taking Lonsurf? *

What are other drugs people take besides Lonsurf? *

Fluorouracil: 11 people, 84.62%
Oxaliplatin: 10 people, 76.92%
Vectibix: 6 people, 46.15%
Capecitabine: 4 people, 30.77%
Zaltrap: 1 person, 7.69%
Xeloda: 1 person, 7.69%
Stivarga: 1 person, 7.69%
Irinotecan Hydrochloride: 1 person, 7.69%
Avastin: 1 person, 7.69%

What are other side effects people have besides Skin toxicity? *

Acute Respiratory Failure: 6 people, 46.15%
Tracheal Stenosis (narrowing of trachea): 6 people, 46.15%
Post Procedural Complication: 6 people, 46.15%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 6 people, 46.15%
Neck Pain: 6 people, 46.15%
Dyspnea (difficult or laboured breathing): 6 people, 46.15%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 5 people, 38.46%
Drug Ineffective: 4 people, 30.77%
Hypersensitivity: 4 people, 30.77%
Death: 2 people, 15.38%

What are the existing conditions these people have? *

Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 7 people, 53.85%
Rectal Cancer (cancer of rectum): 2 people, 15.38%
Metastatic Neoplasm (spreadable cancer tumour): 1 person, 7.69%
Metastases To Lung (cancer spreads to lung): 1 person, 7.69%
High Blood Pressure: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Lonsurf and have Skin toxicity?

- Check whether Skin toxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lonsurf:

Lonsurf (10,077 reports)

Skin toxicity treatments and more:

Skin toxicity (5,295 reports)

How severe was Skin toxicity and when was it recovered:

Skin toxicity in Lonsurf

Expand to all the drugs that have ingredients of tipiracil hydrochloride; trifluridine:

Skin toxicity and drugs with ingredients of tipiracil hydrochloride; trifluridine

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lonsurf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin toxicity:

Skin toxicity (270 drugs)

Browse all the conditions that are associated with Skin toxicity:

Skin toxicity (376 conditions)

Related publications that referenced our studies

Kim DJ, Lee SC, Park GS, Kim GJ, Hwang WT, Lee CS, Lee MH, Hahn DH, Koh HC, "Amiodarone Induced Multiorgan Toxicity in a Patient of Hypertrophic Cardiomyopathy With Atrial Fibrillation", Journal of the Korean Geriatrics Society, 2013 Dec .
Kim DJ, Lee SC, Park GS, Kim GJ, Hwang WT, Lee CS, Lee MH, Hahn DH, Koh HC, "Amiodarone Induced Multiorgan Toxicity in a Patient of Hypertrophic Cardiomyopathy With Atrial Fibrillation", Journal of the Korean Geriatrics Society, 2013 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on tipiracil hydrochloride; trifluridine (the active ingredients of Lonsurf) and Lonsurf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.